Tourmaline Bio, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Tourmaline Bio, a late-stage clinical biotechnology company, announced positive topline data from its Phase 2 TRANQUILITY trial for pacibekitug in cardiovascular inflammation and extended its cash runway into the second half of 2027.
Tourmaline Bio, a late-stage clinical biotechnology company, announces its Q1 2025 financial results and provides updates on its ongoing clinical trials for pacibekitug.
Tourmaline Bio reports a net loss of $20.2 million for the third quarter of 2024, alongside significant increases in research and development spending.
Tourmaline Bio reports a net loss of $17.5 million for the second quarter of 2024, alongside updates on clinical trials and financial position.
Tourmaline Bio's first quarter 2024 report highlights increased spending on research and development, a successful public offering, and progress in clinical trials for their lead drug candidate, TOUR006.